341 related articles for article (PubMed ID: 16807619)
1. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[TBL] [Abstract][Full Text] [Related]
2. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
3. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
4. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA; Punzi CF
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[TBL] [Abstract][Full Text] [Related]
5. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
[TBL] [Abstract][Full Text] [Related]
6. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of eprosartan in diabetic hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
[TBL] [Abstract][Full Text] [Related]
9. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Munoz A; Aznar J
Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
[TBL] [Abstract][Full Text] [Related]
10. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
[TBL] [Abstract][Full Text] [Related]
11. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.
Breeze E; Rake EC; Donoghue MD; Fletcher AE
J Hum Hypertens; 2001 Dec; 15(12):857-62. PubMed ID: 11773988
[TBL] [Abstract][Full Text] [Related]
12. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A; Hanon O; Negre-Pages L; Sevenier F;
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A; Verboom CN; Jäger B
J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
[TBL] [Abstract][Full Text] [Related]
15. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
Rake EC; Breeze E; Fletcher AE
J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
[TBL] [Abstract][Full Text] [Related]
17. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[TBL] [Abstract][Full Text] [Related]
18. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
19. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
[TBL] [Abstract][Full Text] [Related]
20. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]